Aktienanalyse zu Johnson & Johnson (JNJ)JNJJohnson & Johnson

Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. Its segments include Innovative Medicine and MedTech. The Innovative Medicine segment focuses on various therapeutic areas, oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases and cardiovascular and metabolism. Its products include CARVYKTI (ciltacabtagene autoleucel), DARZALEX (daratumumab), DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), ERLEADA (apalutamide), among others. The MedTech segment develops and manufactures a broad portfolio of products used in cardiovascular, orthopedics, surgery, and vision supporting physicians, hospitals, eye care professionals and healthcare systems across a range of acute and elective procedures. The Cardiovascular portfolio includes electrophysiology products. It is also focused on proprietary Firelink degrader antibody conjugate platform. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Johnson & Johnson is a good buy right now, as it is currently priced at $263.81, with a forward P/E ratio of 21.01 indicating reasonable valuation for future earnings growth. The stock has shown a year-to-date change of +27.23%, reflecting strong performance in a challenging market. However, the main risk is the insider selling activity, which has increased by 159.20% over the last month, indicating potential concerns from insiders about future performance.

23 analysts cover JNJ: 12 rate it Buy, 8 Hold and 3 Sell. The average price target is 218.50.